J&J Covid-19 Vaccine Appears to be Safe

A total of 800 adults aged 18 to 55 or aged 65 and up were randomized to various combinations of low-dose or high-dose vaccines or placebo, given 56 days apart.

Adverse events were common, with fatigue, headache, myalgia, and injection-site pain reported most often. At day 29 after the first dose, the seroconversion rate was 99% or more in the younger cohort across dosing groups. Older vaccine recipients had a 96% seroconversion rate. At 57 days after the first dose, antibody titers had increased further.

COVID-19: Single Dose of J&J Vaccine / Plasma / New Testing Requirement — https://www.jwatch.org/fw117413/2021/01/13/covid-19-single-dose-j-j-vaccine-plasma-new-testing

The J&J vaccine is in a multi-center, placebo-controlled, phase 1–2a trial. Here’s the link to the NEJM article https://www.nejm.org/doi/full/10.1056/NEJMoa2034201

From Stat Phase 3 results are coming soon.

There are two Phase 3 studies running. A 40,000-volunteer study of the one-dose vaccine, conducted in the U.S., is set to read out in the next two weeks. A second, equally big study is being conducted using the same vaccine given as two doses, each administered 57 days apart, in case the vaccine does not prove effective in a one-dose regimen or there are other advantages, such as the durability of the vaccine, to giving a second dose.

https://www.statnews.com/2021/01/13/data-fuel-debate-over-whether-jjs-one-dose-covid-vaccine-will-measure-up/ — Data fuel debate over whether J&J’s one-dose Covid vaccine will measure up

And from the Medscape article.

Unlike the Pfizer/BioNTech and Moderna messenger RNA vaccines, the Johnson & Johnson product is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein.

The Next Likely COVID-19 Vaccine Has Its Advantages — https://www.medscape.com/viewarticle/944151?src=rss

SARS-CoV-2 May Be Transmissible Via “Normal Breathing”

SARS-CoV-2 May Be Transmissible Via “Normal Breathing”

SARS-CoV-2, the virus that causes novel coronavirus disease (COVID-19), may be aerosolized “from normal breathing,” according to a letter by a committee of the National Academies of Sciences, Engineering, and Medicine.

Covid-19 — Navigating the Uncharted – MUST READ

This suggests that the overall clinical consequences of Covid-19 may ultimately be more akin to those of a severe seasonal influenza (which has a case fatality rate of approximately 0.1%) or a pandemic influenza (similar to those in 1957 and 1968) rather than a disease similar to SARS or MERS, which have had case fatality rates of 9 to 10% and 36%, respectively.2

Click here to read the full NEJM Editorial.

I’m hoping the NEJM editorial gets read and shared widely.  Clearly all individuals and businesses need to be prepared for the worst case scenario.  If you manage a large company, go back and review/revise your disaster recovery/business continuation plans. I’d make absolutely certain your tele-commuting platform is A+ and working as well as possible.  You may even consider expanding your remote work capabilities because every one of your employees might be using it.  Soon.